Abstract | OBJECTIVE: METHODS: We systematically searched the PubMed, MEDLINE, and Cochrane Library databases and the ClinicalTrials.gov website for studies. We performed a meta-analysis using weighted mean differences (WMD) and 95% confidence intervals in a random-effects model. We assessed between-study heterogeneity using the Cochran's Q and I(2) statistics. RESULTS: Eight randomized, controlled trials with a total of 476 subjects were included in the meta-analysis. Compared with placebos, genistein was effective in reducing plasma levels of homocysteine (WMD, -0.58 μmol/l; p = 0.001), and increasing high density lipoprotein ( HDL) cholesterol levels (WMD, 4.9 mg/dl; p = 0.0002). Subgroup analyses revealed that genistein significantly decreased the levels of low density lipoprotein ( LDL) cholesterol (WMD, -16.90 mg/dl; p = 0.01), total cholesterol (WMD, -15.83 mg/dl; p = 0.008), and triglycerides (WMD, -46.58 mg/dl; p = 0.03) in postmenopausal women with metabolic syndrome, but had no significant effects in those with no metabolic syndrome. CONCLUSIONS:
|
Authors | J Li, Y Liu, T Wang, L Zhao, W Feng |
Journal | Climacteric : the journal of the International Menopause Society
(Climacteric)
Vol. 19
Issue 5
Pg. 440-7
(Oct 2016)
ISSN: 1473-0804 [Electronic] England |
PMID | 27338295
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Cholesterol, HDL
- Cholesterol, LDL
- Triglycerides
- Homocysteine
- Genistein
|
Topics |
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Female
- Genistein
(adverse effects, pharmacology)
- Homocysteine
(blood)
- Humans
- Metabolic Syndrome
(blood)
- Middle Aged
- Postmenopause
(blood)
- Randomized Controlled Trials as Topic
- Triglycerides
(blood)
|